In humans, cytoskeletal dystrophin and muscle LIM protein (MLP) gene mutations can cause dilated cardiomyopathy, yet these mutations may have different effects in mice, owing to increased accumulation of other, compensatory cytoskeletal proteins. Consequently, we characterized left-ventricular (LV) morphology and function in vivo using high-resolution cinemagnetic resonance imaging (MRI) in 2-to 3-month old dystrophin-deficient (mdx) and MLPnull mice, and their respective controls. LV passive stiffness was assessed in isolated, perfused hearts, and cytoskeletal protein levels were determined using Western blot analyses. In mdx mouse hearts, LV-to-body weight ratio, cavity volume, ejection fraction, stroke volume, and cardiac output were normal. However, MLP-null mouse hearts had 1.2-fold higher LV-to-body weight ratios (P<0.01), 1.5-fold higher end-diastolic volumes (P<0.01), and decreased ejection fraction compared with controls (25% vs. 66%, respectively, P<0.01), indicating dilated cardiomyopathy and heart failure. In both models, isolated, perfused heart end-diastolic pressure-volume relationships and passive left-ventricular stiffness were normal. Hearts from both models accumulated desmin and β-tubulin, mdx mouse hearts accumulated utrophin and MLP, and MLP-null mouse hearts accumulated dystrophin and syncoilin. Although the increase in MLP and utrophin in the mdx mouse heart was able to compensate for the loss of dystrophin, accumulation of desmin, syncoilin and dystrophin were unable to compensate for the loss of MLP, resulting in heart failure.
gene encoding dystrophin, a subsarcolemmal protein of the muscle cytoskeleton, which abolish or diminish its expression or which truncate the protein product, cause dilated cardiomyopathy, muscular dystrophy, and frequently both together (4) . Mis-sense mutations in the muscle LIM protein (MLP) gene, encoding another cytoskeletal protein, cause dilated cardiomyopathy or hypertrophic cardiomyopathy in patients due to amino-acid substitutions that disrupt MLP's interaction with T-cap or α-actinin (5-7). The mechanisms that link these cytoskeletal gene mutations with dilated cardiomyopathy are unclear, but a defective response to mechanical stress may be involved, with dystrophin mutations leading to sarcolemmal weakness and aberrant signaling and MLP mutations leading to the loss of a stretch-sensing complex (5, 8, 9) .
Dystrophin-deficient (mdx) and MLP-null mice model the muscle disease associated with mutation of their respective genes in humans. Mdx mice reproduce many of the biochemical changes associated with human dystrophin-deficiency, such as decreased dystrophin-associated glycoprotein complex and neuronal nitric oxide synthase (nNOS) levels and increased utrophin levels (10) (11) (12) . Although better known as a model of muscular dystrophy, there is evidence of mild cardiomyopathy in mdx mice that includes ECG abnormalities, depressed function in the isolated working heart, histological changes and activation of hypertrophic signaling pathways (8, 12, 13) . Mdx mice have also been used to test treatments for dystrophic cardiomyopathy (14, 15 ), yet surprisingly, there have been no in vivo studies of cardiac morphology and function. By contrast, MLP-null mouse hearts reproduce the morphological, functional, biochemical, and gene expression changes associated with MLP gene mutations and dilated cardiomyopathy in patients (5, 16, 17) , and have been used to identify therapeutic targets in dilated cardiomyopathy (18, 19) .
Accurate characterization of the effects of cytoskeletal gene defects in the mouse is important for understanding disease pathogenesis in patients and for the development of new therapies. Highresolution cine-MRI provides accurate, volumetric information on cardiac structure, has the ability to detect subtle alterations in heart morphology and function, and offers a powerful way of characterizing murine cardiomyopathy in vivo (20, 21) . Consequently, we used this technique to determine the effects of dystrophin deficiency in the mouse heart and to compare the mdx model with the MLP-null mouse. Dystrophin loss increases diaphragm muscle compliance (9), so we measured the effects of dystrophin-or MLP-loss on passive ventricular properties in the isolated perfused heart. Elevated levels of utrophin, the dystrophin homologue, may retard disease progression in dystrophin deficiency (11) , whereas the disordered accumulation of microtubules and desmin in pressure overload hypertrophy and idiopathic dilated cardiomyopathy can impair contractile function (22) (23) (24) . Consequently we examined the relationship between cytoskeletal protein levels and cardiac phenotype in dystrophin-and MLPdeficient mice.
MATERIALS AND METHODS

Animals
Two-to three-month-old male mdx and MLP-null mice, and their respective control C57BL/10 and Sv129/B6 strains, were used for comparison with other studies (8, 12, 16) . All experiments were carried out in accordance with Home Office guidelines on the management and welfare of laboratory animals.
Cine magnetic resonance imaging
Cine-MRI was performed as described previously (21) . Briefly, mouse anesthesia was induced in a chamber with isoflurane, vaporized to 4% in pure oxygen. Animals (n = 6, all groups) were positioned supine in a purpose-built mouse holder and maintained at 1.5-2% isoflurane at 1 l/min oxygen flow throughout the MRI experiments. Mouse hearts were imaged using an 11.7 T vertical magnet (Magnex Scientific, Oxon, United Kingdom) equipped with a Bruker Avance console (Bruker Medical, Ettlingen, Germany) and a shielded gradient system (Magnex Scientific). Nine-to-eleven ECG-and respiration-gated, contiguous 1-mm-thick slices spanning the entire left ventricle (LV) were acquired using a fast low-angle shot (FLASH) imaging sequence, with an in-plane pixel resolution of 50 × 50 µm after image reconstruction. At the end of the protocol, all animals recovered from anesthesia on a heated pad, under careful supervision. LV mass and volumes were derived from end-diastolic and end-systolic frames by segmentation, using the software Scion Image for Windows Beta 4.0.2 (Scion Corporation, Frederick, MD, USA). LV mass within each slice was obtained by multiplying wall volume by the specific gravity of muscle, 1.05 g/cm 3 (25) . On the basis of end-systolic and end-diastolic volumes (ESV and EDV, respectively), the following parameters were calculated: stroke volume (SV = EDV -ESV), ejection fraction (EF = SV/EDV × 100) and cardiac output (CO = SV × heart rate).
Langendorff perfusion
C57BL/10 and mdx mice (n = 5, both groups), or Sv129/B6 and MLP-null mice (n = 6, both groups), were heparinized (5000 U/kg body weight) and anesthetized with pentobarbitone (140 mg/kg body weight), administered intraperitoneally. After cessation of peripheral nervous function, hearts were isolated, arrested in Krebs-Henseleit (K-H) buffer, and cleaned of excess tissue. Hearts were cannulated with a 20-gauge needle via the ascending aorta, and an incision was made in the pulmonary artery to prevent venous pressure accumulation. Hearts were perfused in the Langendorff-mode at a constant pressure of 80 mmHg, using Krebs-Henseleit buffer gassed with 95% O 2 /5% CO 2 containing (in mM): 118 NaCl, 4.7 KCl, 1.2 MgSO 4 , 2.25 CaCl 2 , 0.5 Na 2 EDTA, 25 NaHCO 3 , 1.2 KH 2 PO 4 , 11 D-glucose, 1.8 Na-pyruvate, and 0.2 Nalactate. Cardiac function was measured with a water-filled, intraventricular polyvinyl chloride balloon connected by polyethylene tubing to a pressure transducer (AD Instruments Ltd.), which was linked via a PowerLab/8 s digitizer (AD Instruments Ltd.) to a PC that continuously recorded function using Chart TM software (AD Instruments Ltd.). The balloon was inserted through the mitral valve into the left ventricular cavity and inflated, using a water-filled syringe, to give an end-diastolic pressure (EDP) of 4 mmHg, and the pressure transducer was calibrated using a mercury manometer. After a 10 min equilibration period, the balloon was deflated until EDP equaled 0 mmHg; the balloon volume at this point was defined as V 0 , and volumes greater than V 0 caused the development of positive EDPs. Balloon volume was then incrementally increased with water, in 1-µl steps every 10 s, until the EDP was greater than 30 mmHg. This was repeated at least once to ensure reproducibility, and the EDP-EDV data, over a 0-30 mmHg EDP range, were fitted to a monoexponential function, using the equation (26):
Coefficients A and k were estimated using iterative, nonlinear optimization (Microsoft Excel, Solver Add-In). The gradient of the end-diastolic pressure-volume relationship (EDPVR), k, was the left-ventricular chamber stiffness constant. With each group, the mean EDP ± SEM for each balloon volume was calculated and depicted in graph form. After the EDPVR had been measured, the balloon was removed from the heart, and the same analysis was performed outside the LV to confirm that pressure developed by balloon stretch did not contribute to LV EDP measurement.
Protein extraction and immunoblotting
C57BL/10 and mdx mice (n = 3-5 per group), or Sv129/B6 and MLP-null mice (n = 4, both groups), were heparinized (5000 U/kg body weight) and anaesthetized with pentobarbitone (140 mg/kg body weight), administered intraperitoneally. Whole mouse heart or diaphragm muscle was homogenized in lysis buffer containing 75 mM Tris pH 6.8, 3.8% SDS, 4 M urea, 20% glycerol, and heated at 100°C for 5 min. Total protein content was measured (Pierce, Rockford, IL), and 5% β-mercaptoethanol added. Equal amounts of protein were separated on 10% (6% for dystrophin and utrophin) SDS-polyacrylamide gels and electroblotted onto nitrocellulose membranes (BioTrace™ NT 0.45 µm, Pall Gelman Sciences). Membranes were blocked overnight in TBS-tween (TBS-T) containing 5% nonfat dry milk, and incubated with primary antibody for 1 h. After washing for 8 × 15 min in TBS-T, blots were incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Proteins were visualized using the ECL Plus detection system (Amersham Pharmacia Biotech, Piscataway, NJ). After exposure to autoradiography film (MI-NP30 Chemiluminescence film, Fuji), proteins were quantified using QuantiScan software (Biosoft). Primary antibodies used were as follows: anti-β-myosin heavy chain (anti-β-MyHC, NOQ7.5.4D, Sigma), antidystrophin (Dy8/6C5, gift from L. Anderson, Newcastle), antiutrophin (MANCHO3, gift from G.E. Morris (27), antisyncoilin (K. E. Davies), anti-β-tubulin (DM1B, NeoMarkers), antidesmin (DE-U-10m, Sigma), anticalsequestrin (Affinity BioReagents), anti-GAPDH (Chemicon) and anti-MLP C terminus (gift, P. Caroni, Zurich). Mdx and MLP-null mouse cytoskeletal protein levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and calsequestrin (CSQ), respectively, because levels of these proteins were unchanged in cardiac tissue from these models (13, 19) .
Serum creatine kinase activity
C57BL/10 and mdx mice (n = 3, both groups), or Sv129/B6 and MLP-null mice (n = 5, both groups), were anaesthetized by CO 2 inhalation. Following loss of pedal reflexes, thoracotomy was performed to expose the heart for blood collection by cardiac puncture. Blood samples were incubated at room temperature for 30 min to allow time for clotting, before centrifugation at 14,000 rpm for 10 min. Supernatant (serum) was removed and stored at -80°C for subsequent measurement of creatine kinase (CK) activity, using a creatine phosphokinase assay kit (Sigma).
Statistics
All data are expressed as means ± SEMs. Differences between two groups were assessed using ANOVA. Significance was defined as a P value of less than 0.05 (95% confidence).
RESULTS
Markers of dystrophic and cardiac pathology
Compared with C57BL/10 controls, mdx mouse hearts lacked dystrophin, had normal β-myosin heavy chain levels (1.3±0.4 vs. 1.0±0.3) and 14-fold higher serum creatine kinase activities (P<0.01), confirming their dystrophic phenotype (Fig. 1) . By contrast, levels of β-MyHC were increased in MLP null mouse hearts, relative to Sv129/B6 controls, to the extent that they could not be accurately quantified. Serum CK activity was normal in MLP null mice.
In vivo morphology and function
Representative short-axis MRI images are shown in Fig. 2 , and the cardiac morphology and function data are given in Table 1 . In mdx mice, body weight and all cardiac parameters were the same as their C57BL/10 controls. The body weight of MLP-null mice was 8% lower than Sv129/B6 controls (P < 0.05), which contributed to a 37% increase in heart-to-body weight ratio and a 20% increase in LV mass-to-body weight ratio (P < 0.01). Compared with controls, enddiastolic and end-systolic volumes were 52% (P<0.01) and 340% (P<0.01) higher in MLP-null mouse hearts, respectively, and stroke volume and cardiac output were decreased by 44% and 46%, respectively (P<0.01). MLP-null mouse LV ejection fraction was 25%, significantly lower than control, which was 66% (P<0.01).
Pressure-volume relationships
Isolated, perfused mdx mouse hearts had the same end-diastolic pressure-volume relationships as their C57BL/10 controls over the EDP range 0-30 mmHg (Fig. 3) . Estimated passive LV stiffness constants for control and mdx mice were 0.027 ± 0.002 and 0.028 ± 0.003, respectively. The end-diastolic pressure-volume relationship of MLP-null mouse hearts was also similar to Sv129/B6 controls, and the LV stiffness constants in control and MLP-null hearts, 0.033 ± 0.004 and 0.029 ± 0.001, respectively, were not significantly different (Fig. 3) .
Cytoskeletal protein levels
In the mdx and MLP-null mouse heart levels of β-tubulin were increased 1.4-fold and 1.9 fold, respectively, and desmin levels were increased 1.4-fold and 4-fold, respectively, compared with their controls (Figs. 4 and 5) . Dystrophin-deficient mouse hearts had 1.7-fold higher MLP levels and MLP-null hearts had 2.3-fold higher dystrophin levels, relative to controls. Additionally, mdx mouse hearts accumulated utrophin (2.1-fold), and MLP-null mouse hearts accumulated syncoilin (2.9-fold). In mdx diaphragm muscle, levels of syncoilin, β-tubulin, desmin, and MLP were significantly higher than in controls (P<0.05; Table 2 ), whereas cytoskeletal protein levels were normal in MLP-null diaphragm.
DISCUSSION
Dystrophin-deficient mice had elevated serum CK activity, consistent with muscular dystrophy, but normal cardiac morphology and function and normal levels of β-myosin heavy chain protein.
MLP-null mice, by contrast, had normal serum CK activity, but left-ventricular chamber dilation with impaired function and greatly elevated cardiac β-MyHC levels. Cytoskeletal proteins accumulated in hearts from both models, but only in dystrophic diaphragm muscle.
To our knowledge, this is the first high-resolution cine MR-imaging study of dystrophic and MLP-null mouse hearts. Dystrophin deficiency in the human heart is often associated with dilated cardiomyopathy (28), and post-translational modification of dystrophin may contribute to the pathogenesis of idiopathic dilated cardiomyopathy and cardiomyopathy caused by enteroviral infection (2, 29) . In an earlier study, we found that young mdx mice had normal heart weights and ECGs (12) , and here, we have shown an absence of morphological or functional impairment in vivo, perhaps due to compensatory up-regulation of utrophin and other cytoskeletal proteins (10, 30) . Impaired LV function has been reported in young, isolated, buffer-perfused working mdx mouse hearts, which also had increased susceptibility to damage caused by isoproterenol injection and aortic banding (8) . We may also have found significant LV morphology and function abnormalities in vivo, compared with control mice, had we chronically increased cardiac workload. Histological and ECG changes increase with age in the mdx mouse (12, 31), therefore alteration of cardiac morphology and basal function may occur later in life.
In contrast to mdx mice, 2-to 3-month-old MLP-null mice had greater heart and LV weights, when normalized to body weight, than their controls, indicating cardiac hypertrophy, as reported previously by autopsy (16) . End-diastolic and end-systolic volumes were increased 1.5-and 3.4-fold, respectively, and ejection fraction, stroke volume and cardiac output were decreased 44-62% in MLP null mice, indicating dilated cardiomyopathy with heart failure. Increased enddiastolic dimensions and reduced fractional shortening in MLP null mice have been found using M-mode echocardiography (16, 19, 32 ), but our MRI results provide more accurate measures of LV mass and volumes in end-diastole and end-systole and thus stroke volumes, ejection fractions, and cardiac output (21) . Consistent with the contrasting pathologies of dystrophin-and MLP-deficient mouse hearts, β-MyHC protein levels were increased, as found for β-MyHC mRNA using dot blot analyses (19) , only in MLP-deficiency, suggesting hypertrophy and fetal gene expression in this model. Diastolic function is affected by isovolumic relaxation and diastolic filling, both of which may be impaired in dystrophin-deficient patients (33). Impaired diastolic relaxation was found in isolated, working mdx mouse hearts (8) , but here, we found a normal end-diastolic pressurevolume relationship in isolated, Langendorf-perfused hearts, so it may be that diastolic dysfunction in the mdx mouse heart could have been revealed under conditions of increased mechanical stress. Passive LV stiffness is affected by muscle viscoelastic properties (including myocardial stiffness), RV properties and constraint from the pericardium (34), but the dominating influence is the LV cavity-to-wall volume ratio (35) . Since LV stiffness and chamber morphology were normal in mdx mice, our results would suggest that the underlying myocardial stiffness was also unaffected by dystrophin loss. Similarly, it was reported that desmin deficiency in the mouse did not alter myocardial stiffness (36) .
We also found that passive LV properties were unaffected by MLP-loss in the mouse. This contrasts with two other studies on the MLP null mouse: increased passive LV stiffness was reported in 3-to 6-month-old animals using the balloon-in-ventricle technique, and was associated with increased collagen deposition and increased myocardial stiffness (37); decreased myocardial stiffness was reported in papillary muscle from 2-week-old mice, before the onset of dilated cardiomyopathy and heart failure, suggesting that myocardial material properties were directly affected by MLP deficiency (5). Our mice were of intermediate age (2-3 months old) relative to these earlier studies; therefore, an elevation of LV chamber stiffness may have occurred later in their disease progression, because cardiac function continues to deteriorate in MLP null mice (38) or, as mentioned above for the mdx mouse heart, diastolic dysfunction may have been revealed under conditions of increased mechanical stress. Despite increased myocardial stiffness, LV stiffness may be normal in dilated cardiomyopathy patients due to the opposing effect of chamber dilation (39) , so the same may have applied to the MLP null mice studied here. In short, despite marked changes in expression of cytoskeletal proteins, passive LV stiffness in the ex vivo mdx and MLP null Langendorff-perfused mouse hearts, was found to be normal.
Loss of dystrophin or MLP in the mouse heart and in dystrophic diaphragm muscle resulted in increased levels of cytoskeletal proteins that were associated with the dystrophin/utrophinassociated protein complex (dystrophin, utrophin, syncoilin), the intermediate filament network (desmin, syncoilin), microtubules (β-tubulin) or the interface between the Z-disk and the extrasarcomeric cytoskeleton/intercalated disk (desmin, MLP). It is unclear why cytoskeletal proteins accumulated in dystrophin-and not MLP-deficient diaphragm. One reason may be their contrasting pathologies, because mdx mouse diaphragm is severely affected, whereas skeletal muscle pathology was reportedly mild in MLP-null mice (16, 40) . Alternatively, different expression levels of dystrophin and MLP in diaphragm may underlie a differential sensitivity to the loss of these proteins. In control animals, we found high dystrophin levels in cardiac and diaphragm muscle, but high MLP levels in cardiac muscle only. Relative to slow skeletal muscle fibers, fast muscles express slightly less dystrophin and considerably less MLP (41, 42) ; therefore, in diaphragm, a muscle of mainly fast-twitch fibers, loss of dystrophin perhaps had a significantly greater impact on remodeling than MLP-loss.
Both β-tubulin and desmin accumulated in dystrophin-and MLP-deficient hearts, and in dystrophin-deficient diaphragm. Consistent with this, previous skeletal muscle studies have reported elevated α-and β-tubulin mRNA levels in mdx mice and increased α-tubulin mRNA and desmin protein levels in DMD patients, the latter associated with muscle regeneration (43) (44) (45) . Injured cardiac muscle and mdx diaphragm lack the ability to make significant repairs by regeneration (46, 47) , suggesting that desmin accumulation was not associated with this process, like utrophin accumulation (30). In idiopathic dilated cardiomyopathy, increased β-tubulin, microtubule and desmin content was reported (23, 24), and microtubule accumulation in pressure-overload hypertrophy caused contractile dysfunction associated with increased cytoskeletal, cardiomyocyte and myocardial viscosity (22, 48) . LV function and passive properties were not impaired in mdx mice, and these animals had a near-normal lifespan (10), suggesting that β-tubulin and desmin accumulation was not maladaptive and that these proteins may accumulate in the absence of morphological or functional cardiac remodeling. By contrast, β-tubulin and desmin accumulation in MLP-null mouse hearts was associated with dilated cardiomyopathy and heart failure, and therefore, may have contributed to disease pathogenesis.
Utrophin levels were also higher in mdx mouse heart, as reported previously, probably for structural compensation. In MLP-null mouse heart, utrophin content was normal, perhaps because dystrophin levels were increased instead. We also found MLP accumulation in dystrophin-deficient mouse heart and diaphragm muscle. Elevated MLP levels have been associated with increased sarcomeric organization in hypertrophying cardiomyocytes (49) , and with fast-to-slow shifts in myosin heavy chain isoforms during skeletal muscle stimulation (50, 51) . However, mdx mice lacked cardiac hypertrophy, and it is not clear whether mdx diaphragm muscle had a slower phenotype than control. Increased nitric oxide synthase (NOS) activity and NO production suppressed MLP expression in isolated myocytes (49) , therefore, loss of sarcolemmal nNOS, which occurs in mdx mouse striated muscle (12, 52, 53) , perhaps caused an increase in MLP expression. Levels of syncoilin, a desmin-binding intermediate filament protein of the dystrophin-associated protein complex, may be increased in response to muscle damage (54, 55) , hence, the increase in mdx and MLP-null mouse diaphragm and heart, respectively, since these muscles are most severely affected in these models.
It is surprising that similar cytoskeletal proteins accumulated in mdx mouse hearts, which were morphologically and functionally normal, and MLP null mouse hearts, which had marked LV dilation and heart failure. There is evidence of structural compensation for dystrophin deficiency by utrophin, talin, and vinculin in mdx skeletal muscle, and by utrophin in mdx cardiac muscle (56, 57) . The current study suggests that β-tubulin, desmin, and MLP may also help structurally compensate for the loss of dystrophin in mdx cardiac and diaphragm muscle. It is also possible that cytoskeletal protein accumulation was compensatory in MLP-deficiency, but was not sufficient to prevent morphological and functional remodeling.
The absence of morphological or functional changes in the mdx mouse heart casts doubt on the suitability of this model for developing treatments of patient cardiac disease associated with dystrophin-deficiency. We used 2-to 3-month old mice because this age is commonly used for mdx mouse heart studies, but there is evidence that cardiac disease is more severe in older animals (31), which may therefore manifest as morphological or functional changes. By contrast, 2-to 3-month-old MLP-null mice had dilated cardiomyopathy and heart failure, as reported by others using echocardiography (16) . Differences in genetic background may underlie the markedly different phenotypes of dystrophin and MLP-deficient mouse hearts, since the cardiac disease of MLP-null mice was sensitive to background strain (58), and we found differences in heart rate, heart-to-body weight ratio, LV mass, stroke volume, and ejection fraction between the C57BL/10 and Sv129/B6 control strains (Table 1) . It is possible that dystrophin deficiency on an Sv129/B6 background would reproduce the dilated cardiomyopathy frequently associated with patient dystrophin mutations.
The current data provide accurate, in vivo quantification of cardiac morphological and functional parameters of mdx and MLP-null mice and show that, despite very different cardiac phenotypes, there is a similar accumulation of cytoskeletal proteins in both models that may provide structural compensation, although this was insufficient to prevent cardiac disease in MLPdeficiency.
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